Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat plus dapagliflozin for prevention of incident heart failure in high-risk adults with type 2 diabetes and cardiovascular disease
NL-OMON58886Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) comparing Baxdrostat + dapagliflozin with Placebo + dapagliflozin (2 arms). Started May 2025; status: recruiting.
02
Drugs
baxdrostatdapagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NL-OMON58886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58886.